PD1 inhibitors such as sintilimab (ORIENT-16) (56, 57) and pembrolizumab (KEYNOTE-859) (58) combined with standard chemotherapy can enhance the survival prognosis in advanced HER2-negative GC cases. Here, PDCD1 is linked to gastric cancer.